Inhalation Sciences Sweden
Inhalation Sciences Q1 2023: Heading towards break-even (Redeye)

2023-06-01 07:30
Redeye provides an update in relation to ISAB’s Q1 2023 report. Net sales during the quarter amounted to SEK3.2m (SEK2.1m), 28% lower than our sales estimate of SEK4.5m, and EBIT came in at SEK-2.1m (SEK-3.4m), in line with our expectations of SEK-2.0m. We have chosen to make some minor changes in our sales and OPEX estimates. However, this does not render any changes in our fair value range.

info@redeye.se (Redeye.se)
Redeye AB - Redeye.se

Inhalation Sciences - I dag

{point.key}

Marknadsöversikt

Stockholmsbörsen, OMXS30

I dag
-
Senast
-
{point.key}

Världsindex

Index +/- % Senast
DAX - -
Hang Seng - -
Nikkei - -

Valutor

Valuta +/- % Senast
USD/SEK - -
EUR/SEK - -
GBP/SEK - -
EUR/USD - -

Räntor

Ränta +/- % Senast
5-års ränta - -
10-års ränta - -

Råvaror

Råvara +/- % Senast
Guld - -
Silver - -
Koppar - -